“Bullish on Symbiotec Pharmalab IPO, assigning an 'apply' tag due to its integrated pharmaceutical and biotechnology platform, strong global presence with 60+ API exports to over 40 countries, and approvals from major regulators like US FDA and EU-GMP. The valuation at 58.36x post-IPO FY26 P/E appears relatively attractive compared to listed peers, suggesting potential for listing gains and future growth.”